Purinergic Receptor Expression and Potential Association with Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Development

OBJECTIVE: Due to recent progress in production of human embryonic stem cell-derived oligodendrocyte progenitor cells (hESC-OPCs) for ameliorating myelin disease such as multiple sclerosis (MS) and the role of purinergic signaling in OPCs development, we avaluated the profile of purinergic receptors expression during development of OPCs from hESC. MATERIALS AND METHODS: In this experimental study, we used reverse transcription and quantitative polymerase chain reaction (RT-qPCR) to obtain more information about potential roles of purinergic receptors during in vitro production of hESC-OPCs. We first determined the expression level of different subtypes of purinergic receptors in hESCs, embryoid bodies (EBs), and hESC-OPCs. The effects of A1adenosine receptor (A(1)AR) activation on hESC-OPCs development were subsequently examined. RESULTS: hESCs and OPCs had different mRNA expression levels of the AR subtypes. ARs mRNA were expressed in the EB stage, except for A(2A)AR. We observed expressions of several P2X (P2X(1, 2, 3, 4, 5, 7)) and P2Y (P2Y(1, 2, 4, 6, 11-14)) genes in hESCs. hESC-OPCs expressed different subtypes of P2X (P2X(1, 2, 3,4,5,7)) and P2Y (P2Y(1, 2, 4, 6, 11-14)). Except for P2X(1) and P2X(6), all other P2X and P2Y purinergic receptor subtypes expressed in EBs. We also indicate that A(1)AR might be involved in modulating gene expression levels of cell cycle regulators in an agonist and/or dose-dependent manner. CONCLUSION: Elucidation of the expression pattern of purinergic receptors and the effects of different subtypes of these receptors in hESC-OPCs may have a promising role in future cell-based therapy or drug design for demyelinating disease.